Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Kathleen Cooney

GU Oncology · Duke

View

Dr. Kimryn Rathmell

GU Oncology · Arthur G James Cancer Hospital

View

Dr. Patrick Pilie

GU Oncology · MD Anderson Cancer Center

View

Dr. Rebecca Shatsky

Breast Oncology · UCSD

View

Dr. Robert Bast

Breast Oncology · MD Anderson Cancer Center

View

Dr. Julia Close

General Oncology · UF

View

Dr. Sara Tolaney

Breast Oncology · Dana-Farber Cancer Institute

View

Dr. Allison Fitzgerald

General Oncology · Dana-Farber Cancer Institute

View

Dr. Jason Mouabbi

Breast Oncology · MD Anderson Cancer Center

View

Dr. Rebecca Miksad

GI Oncology · BMC

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Perioperative Apalutamide in High-Risk Localized Prostate Cancer

    Aug 6, 2026DOI: 10.1056/nejmoa2603878Original ArticleNEJM

    Written by: Mary-Ellen Taplin, M.D.Martin Gleave, M.D.Neal D. Shore, M.D.Angela Lopez-Gitlitz, M.D.Alexander Kretschmer, M.D.Eleni Efstathiou, M.D.Paul L. Nguyen, M.D.Ronaldo Damião, M.D.Toshiyuki Kamoto, M.D., Ph.D.Ashley Ross, M.D., Ph.D.Alberto Briganti, M.D., Ph.D.Boris A. Hadaschik, M.D.Axel Heidenreich, M.D.Álvaro Juárez Soto, M.D.Huihui Ye, M.D.Geoffrey Gotto, M.D., M.P.H.Brendan Rooney, Ph.D.Shaozhou Ken Tian, M.D.Lisa Wetherhold, B.S.Branko Miladinovic, Ph.D.Sharon A. McCarthy, B.Pharm.Christopher P. Evans, M.D.Adam S. Kibel, M.D.

    Find these authors on Roon

    MT
    Dr. Mary-Ellen Taplin
    GU Oncology · Dana-Farber Cancer Institute

    Summary

    In high-risk localized prostate cancer, ADT plus apalutamide led to a pathological complete response or minimal residual disease and 5-year metastasis-free survival in a greater percentage of patients than ADT plus placebo.
    MTDr. Mary-Ellen Taplin

    Dr. Mary-Ellen Taplin

    Medical Oncology · Genitourinary Oncology
    Dana-Farber Cancer Institute
    maryellen